Navamedic ASA (OSL: NAVA)

Market Cap	422.14M
Revenue (ttm)	525.55M
Net Income (ttm)	19.62M
Shares Out	17.66M
EPS (ttm)	n/a
PE Ratio	21.51
Forward PE	15.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,272
Average Volume	7,795
Open	25.00
Previous Close	24.50
Day's Range	25.00 - 25.50
52-Week Range	23.00 - 40.00
Beta	0.45
RSI	43.49
Earnings Date	Feb 12, 2025

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 45
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2023, Navamedic ASA's revenue was 512.00 million, an increase of 33.98% compared to the previous year's 382.14 million. Earnings were 3.30 million, a decrease of -88.77%.